Literature DB >> 18490912

Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab.

Sw Bokhari, E Das-Gupta, Nh Russell, J Byrne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18490912     DOI： 10.1038/bmt.2008.149

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  2 in total

1.  Alemtuzumab in allogeneic hematopoetic stem cell transplantation.

Authors:  Xavier Poiré; Koen van Besien
Journal:  Expert Opin Biol Ther       Date:  2011-06-27       Impact factor: 4.388

2.  EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.

Authors:  C P Fox; D Burns; A N Parker; K S Peggs; C M Harvey; S Natarajan; D I Marks; B Jackson; G Chakupurakal; M Dennis; Z Lim; G Cook; B Carpenter; A R Pettitt; S Mathew; L Connelly-Smith; J A L Yin; M Viskaduraki; R Chakraverty; K Orchard; B E Shaw; J L Byrne; C Brookes; C F Craddock; S Chaganti
Journal:  Bone Marrow Transplant       Date:  2013-11-11       Impact factor: 5.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.